reference/16738939

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16738939

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	306
issn	0923-7534
issueIdentifier	2
pageRange	301-306
publicationName	Annals of oncology : official journal of the European Society for Medical Oncology
startingPage	301
bibliographicCitation	von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, Kreienberg R, Hilfrich J, Gerber B, Hanusch C, Fehm T, Strumberg D, Solbach C, Nekljudova V, Untch M; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie-Brust investigators. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol. 2011 Feb;22(2):301–6. doi: 10.1093/annonc/mdq350. PMID: 20624784.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7ae6b2c5c8246835c9c155bb24cab346 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ec411d34e38242ce97801f3a45cde5d4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d2b7400636a40d2efef86eedaa72a3db http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9a94fc6dc77ec30653797419847fed24 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a0e91dab6119e46a9152de3ac7032212 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7b2c9dc6962961562fa974e995f0b750 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_38f3003705b83122111f3fbc5e118fa1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f8a9f53f36f5d601ce36ee28be6fddd6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2051f30de0d3b13b562f64e23674cddc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9bc1967fb908db11a190bb64716d9b86 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b84a7464bcd831e1812226533c4aab05 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b9d73e6ce40e55d01fd10ea0a6a10d7a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fdbd213ff15c8594371fc2cd160d5287 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a3d346bec4b4b5f981914c7135b5cc46 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_54d5fd3c1bd04e7200c3e4b267ce9392
date	201102
identifier	https://pubmed.ncbi.nlm.nih.gov/20624784 https://doi.org/10.1093/annonc/mdq350
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1846 https://portal.issn.org/resource/ISSN/0923-7534
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
discusses	http://id.nlm.nih.gov/mesh/M0443627 http://id.nlm.nih.gov/mesh/M0029863 http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0018336 http://id.nlm.nih.gov/mesh/M0473129 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M000602394
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000911Q000627 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D001943Q000188 http://id.nlm.nih.gov/mesh/D011799Q000627 http://id.nlm.nih.gov/mesh/D020123Q000031
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000911Q000009 http://id.nlm.nih.gov/mesh/D000911Q000008 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000077341 http://id.nlm.nih.gov/mesh/D061067 http://id.nlm.nih.gov/mesh/D011799Q000009 http://id.nlm.nih.gov/mesh/D011799Q000008 http://id.nlm.nih.gov/mesh/D017024 http://id.nlm.nih.gov/mesh/D020123Q000009 http://id.nlm.nih.gov/mesh/D000068338 http://id.nlm.nih.gov/mesh/D000068258 http://id.nlm.nih.gov/mesh/D020123Q000627 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D020123Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e8ad08f759b2798c1b5dca78861cc6ce http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6442177 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7548 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10389 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9548828 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30323 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10931 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID208908 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8078 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID41867 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID242749350 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127494626 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248766214 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660

Total number of triples: 84.